Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?
Tejera Segura B, Altabás González I, Rúa-Figueroa I, Pérez Veiga N, Del Campo Pérez V, Olivé-Marqués A, Galindo M, Calvo J, Ovalles-Bonilla JG, Fernández-Nebro A, Menor-Almagro R, Tomero E, Del Val Del Amo N, Uriarte Isacelaya E, Martínez-Taboada VM, Andreu JL, Boteanu A, Narváez J, Movasat A, Montilla C, Senabre Gallego JM, Hernández-Cruz B, Andrés M, Salgado E, Freire M, Machín García S, Moriano C, Expósito L, Pérez Velásquez C, Velloso-Feijoo ML, Cacheda AP, Lozano-Rivas N, Bonilla G, Arévalo M, Jiménez I, Quevedo-Vila V, Manero-Ruiz FJ, García de la Peña Lefebvre P, Vázquez-Rodríguez TR, Ibañez-Rua J, Cobo-Ibañez T, Pego-Reigosa JM. Tejera Segura B, et al. Among authors: altabas gonzalez i. Rheumatology (Oxford). 2021 Nov 3;60(11):5329-5336. doi: 10.1093/rheumatology/keab401. Rheumatology (Oxford). 2021. PMID: 33950249
Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review.
García-Beloso N, Altabás-González I, Samartín-Ucha M, Gayoso-Rey M, De Castro-Parga ML, Salgado-Barreira Á, Cibeira-Badia A, Piñeiro-Corrales MG, González-Vilas D, Pego-Reigosa JM, Martínez-López de Castro N. García-Beloso N, et al. Among authors: altabas gonzalez i. Br J Clin Pharmacol. 2022 Feb;88(4):1529-1550. doi: 10.1111/bcp.15101. Epub 2021 Nov 2. Br J Clin Pharmacol. 2022. PMID: 34622969 Free article. Review.
Analysis of the implementation of an innovative IT solution to improve waiting times, communication with primary care and efficiency in Rheumatology.
Pego-Reigosa JM, Peña-Gil C, Rodríguez-Lorenzo D, Altabás-González I, Pérez-Gómez N, Guzmán-Castro JH, Varela-Gestoso R, Díaz-Lambarri R, González-Carreró-López A, Míguez-Senra O, Bóveda-Fontán J, Charle-Crespo Á, Caramés-Casal FJ, Barbazán-Álvarez C, Hernández-Rodríguez Í, Maceiras-Pan F, Rodríguez-López M, Melero-González R, Rodríguez-Fernández JB. Pego-Reigosa JM, et al. Among authors: altabas gonzalez i. BMC Health Serv Res. 2022 Jan 12;22(1):60. doi: 10.1186/s12913-021-07455-4. BMC Health Serv Res. 2022. PMID: 35022061 Free PMC article.
Does expert opinion match the definition of lupus low disease activity state? Prospective analysis of 500 patients from a Spanish multicentre cohort.
Altabás-González I, Rúa-Figueroa I, Rubiño F, Mouriño Rodríguez C, Hernández-Rodríguez I, Menor Almagro R, Uriarte Isacelaya E, Tomero Muriel E, Salman-Monte TC, Carrión-Barberà I, Galindo M, Rodríguez Almaraz EM, Jiménez N, Inês L, Pego-Reigosa JM. Altabás-González I, et al. Rheumatology (Oxford). 2023 Mar 1;62(3):1162-1169. doi: 10.1093/rheumatology/keac462. Rheumatology (Oxford). 2023. PMID: 35961050 Free PMC article.
Tobacco smoking is an independent factor associated with retinal damage in systemic lupus erythematosus: a cross-sectional and retrospective study.
Rúa-Figueroa I, Erausquin C, Rua-Figueroa C, González-Martín J, Naranjo A, Ojeda S, Francisco F, Quevedo JC, Cáceres L, López R, Greco M, Altabás-González I, Pérez Y, Rubiño F, Rodríguez-Lozano C. Rúa-Figueroa I, et al. Among authors: altabas gonzalez i. Rheumatol Int. 2020 Mar;40(3):367-374. doi: 10.1007/s00296-019-04473-8. Epub 2019 Nov 27. Rheumatol Int. 2020. PMID: 31773393
Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients.
Altabás-González I, Pego-Reigosa JM, Mouriño C, Jiménez N, Hernández-Martín A, Casafont-Solé I, Urguelles JF, Román-Ivorra JA, Navarro MR, Galindo-Izquierdo M, Salman-Monte TC, Narváez J, Vidal-Montal P, García-Villanueva MJ, Garrote-Corral S, Blázquez-Cañamero MÁ, Marras C, Piqueras-García M, Martínez-Barrio J, Sánchez-Lucas M, Cortés-Hernández J, Penzo E, Calvo J, de Dios JR, Rodríguez BÁ, Vasques-Rocha M, Tomero E, Menor-Almagro R, Gandía M, Gómez-Puerta JA, Frade-Sosa B, Ramos-Giráldez C, Trapero-Pérez C, Diez E, Moriano C, Muñoz-Jiménez A, Rúa-Figueroa I. Altabás-González I, et al. Rheumatology (Oxford). 2024 Mar 15:kead696. doi: 10.1093/rheumatology/kead696. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38490245
Type I Interferons induce endothelial destabilization in Systemic Lupus Erythematosus in a Tie2-dependent manner.
Rafael-Vidal C, Martínez-Ramos S, Malvar-Fernández B, Altabás-González I, Mouriño C, Veale DJ, Floudas A, Fearon U, Reigosa JMP, García S. Rafael-Vidal C, et al. Among authors: altabas gonzalez i. Front Immunol. 2023 Dec 14;14:1277267. doi: 10.3389/fimmu.2023.1277267. eCollection 2023. Front Immunol. 2023. PMID: 38162654 Free PMC article.
Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?
Altabás-González I, Rúa-Figueroa Í, Rubiño F, Mouriño C, Hernández-Rodriguez Í, Menor-Almagro R, Uriarte-Isacelaya E, Tomero E, Salman-Monte TC, Carrión-Barberá I, Galindo-Izquierdo M, Rodriguez-Almaraz ME, Inês LS, Jiménez N, Pego-Reigosa JM. Altabás-González I, et al. Rheumatology (Oxford). 2024 Jan 4;63(1):72-78. doi: 10.1093/rheumatology/kead159. Rheumatology (Oxford). 2024. PMID: 37039851 Free PMC article.